新生儿临床试验纳入婴儿的种族与民族:一项系统综述
该系统综述检索了2017至2021年Cochrane CENTRAL注册的美国新生儿临床试验,纳入120项研究共14479名参与者。其中75项(62.5%)报告了任何种族或民族数据;在这些研究中,参与者背景的中位数(IQR)为亚洲0%(0%-1%)、黑人26%(9%-42%)、西班牙裔3%(0%-12%)、原住民0%(0%-0%)、多种族0%(0%-0%)、白人57%(30%-68%)、其他7%(1%-21%)。与佛蒙特牛津网络美国NICU人群参考样本相比,亚洲、黑人、西班牙裔和原住民参与者代表性不足,白人参与者过度代表;许多参与者被标记为其他种族但描述不足,报告术语和方法差异大,地理上偏重东北部,近四分之一州未覆盖。作者建议资助者和临床试验者考虑三点针对性措施以解决这些问题。
要点
- 120项美国新生儿临床试验中仅75项(62.5%)报告了任何种族或民族数据。
- 报告种族的研究中,白人参与者中位数57%(30%-68%),黑人26%(9%-42%),西班牙裔3%(0%-12%),亚洲0%(0%-1%),原住民0%(0%-0%)。
- 与佛蒙特牛津网络美国NICU人群参考样本相比,亚洲、黑人、西班牙裔和原住民参与者代表性不足,白人参与者过度代表。
- 许多参与者被标记为其他种族或民族但缺乏充分描述,报告术语和方法差异大。
- 地理分布严重偏重东北部,近四分之一州未在纳入研究中出现。
适用人群与场景
- 2017至2021年Cochrane CENTRAL注册的美国新生儿临床试验,共纳入120项研究、14479名参与者。
研究设计与关键结果
- 系统综述纳入120项研究共14479名参与者,其中75项(62.5%)报告了任何参与者种族或民族数据。
- 在报告种族和民族的研究中,参与者背景的中位数(IQR)为亚洲0%(0%-1%)、黑人26%(9%-42%)、西班牙裔3%(0%-12%)、原住民(如阿拉斯加原住民、美洲印第安人和夏威夷原住民)0%(0%-0%)、多种族0%(0%-0%)、白人57%(30%-68%)、其他种族或民族7%(1%-21%)。
- 与佛蒙特牛津网络美国NICU人群参考样本相比,亚洲、黑人、西班牙裔和原住民参与者代表性不足,白人参与者过度代表。
- 许多参与者被标记为其他种族或民族但缺乏充分描述,报告种族和民族数据的术语和方法存在很大差异。
- 地理代表性严重偏重东北部,近四分之一州未被代表。
证据类型、等级与局限
- 证据类型:系统综述,检索Cochrane CENTRAL 2017至2021年美国新生儿临床试验。
- 由两人独立进行纳入判定、数据提取和质量评估,分歧通过共识裁定。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议:资助者和临床试验者考虑三点针对性措施——优先寻找增加新生儿临床试验参与多样性的方法;就报告新生儿临床试验参与者种族和民族的标准化方法达成一致;优先纳入来自美国所有地区的参与者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Representativeness of populations within neonatal clinical trials is crucial to moving the field forward. Although racial and ethnic disparities in research inclusion are well documented in other fields, they are poorly described within neonatology.
OBJECTIVE: To describe the race and ethnicity of infants included in a sample of recent US neonatal clinical trials and the variability in this reporting.
EVIDENCE REVIEW: A systematic search of US neonatal clinical trials entered into Cochrane CENTRAL 2017 to 2021 was conducted. Two individuals performed inclusion determination, data extraction, and quality assessment independently with discrepancies adjudicated by consensus.
FINDINGS: Of 120 studies with 14 479 participants that met the inclusion criteria, 75 (62.5%) included any participant race or ethnicity data. In the studies that reported race and ethnicity, the median (IQR) percentage of participants of each background were 0% (0%-1%) Asian, 26% (9%-42%) Black, 3% (0%-12%) Hispanic, 0% (0%-0%) Indigenous (eg, Alaska Native, American Indian, and Native Hawaiian), 0% (0%-0%) multiple races, 57% (30%-68%) White, and 7% (1%-21%) other race or ethnicity. Asian, Black, Hispanic, and Indigenous participants were underrepresented, while White participants were overrepresented compared with a reference sample of the US clinical neonatal intensive care unit (NICU) population from the Vermont Oxford Network. Many participants were labeled as other race or ethnicity without adequate description. There was substantial variability in terms and methods of reporting race and ethnicity data. Geographic representation was heavily skewed toward the Northeast, with nearly one-quarter of states unrepresented.
CONCLUSIONS AND RELEVANCE: These findings suggest that neonatal research may perpetuate inequities by underrepresenting Asian, Black, Hispanic, and Indigenous neonates in clinical trials. Studies varied in documentation of race and ethnicity, and there was regional variation in the sites included. Based on these findings, funders and clinical trialists are advised to consider a 3-point targeted approach to address these issues: prioritize identifying ways to increase diversity in neonatal clinical trial participation, agree on a standardized method to report race and ethnicity among neonatal clinical trial participants, and prioritize the inclusion of participants from all regions of the US in neonatal clinical trials.
参考来源
- Lyle ANJ, Shaikh H, Oslin E, et al. Race and Ethnicity of Infants Enrolled in Neonatal Clinical Trials: A Systematic Review. JAMA Netw Open. 2023. PMID: 38127349. doi:10.1001/jamanetworkopen.2023.48882
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。